More on Treatment Outcomes in Multidrug-Resistant Tuberculosis
To the Editor: Zignol et al. (Sept. 15 issue) 1 suggest that within 10 years, molecular technologies will replace conventional phenotypic testing in surveys of drug resistance and surveillance of tuberculosis. To avoid the overestimation of drug resistance, wider implementation of testing for minima...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2016-12, Vol.375 (26), p.2609-2611 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2611 |
|---|---|
| container_issue | 26 |
| container_start_page | 2609 |
| container_title | The New England journal of medicine |
| container_volume | 375 |
| creator | Salfinger, Max Somoskovi, Akos Diacon, Andreas H Van Baelen, Ben Theeuwes, Myriam Brust, James C.M Shah, N. Sarita Gandhi, Neel R Lange, Christoph Günther, Gunar van Leth, Frank |
| description | To the Editor:
Zignol et al. (Sept. 15 issue)
1
suggest that within 10 years, molecular technologies will replace conventional phenotypic testing in surveys of drug resistance and surveillance of tuberculosis. To avoid the overestimation of drug resistance, wider implementation of testing for minimal inhibitory concentration (MIC) must occur first, for four main reasons. First, most commercial molecular assays do not provide information on the type of mutation. Second, different mutation types may be associated with different phenotypic MICs and different clinically relevant levels of resistance, which may lead to unnecessary discontinuation of a drug or incorrectly identifying a patient as . . . |
| doi_str_mv | 10.1056/NEJMc1613123 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1854106634</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1854106634</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4703-14a1b67fd0b2f8ba8ea12302baa1c7ef4d893823f7bfee6247bf7b3115d391083</originalsourceid><addsrcrecordid>eNqN0UtLxDAUBeAgio6jO9dS0IULq7l5Nd0IMowvHAdkXJe0vZUOfWjSLPz3ZhgVEReTzYXk4xDuIeQI6AVQqS6fpg-zAhRwYHyLjEByHgtB1TYZUcp0LJKU75F955Y0HBDpLtljmrI0hXRErma9xajvooVFM7TYDdHcD0XfoovqLpr5ZqhL61_jZ3S1G0x4X_gcbeGbPlwckJ3KNA4Pv-aYvNxMF5O7-HF-ez-5fowLkVAegzCQq6Qqac4qnRuNJvyWstwYKBKsRKlTrhmvkrxCVEyEmeQcQJY8Bar5mJytc99s_-7RDVlbuwKbxnTYe5eBlgKoUlxsSqXclEoZlrsZFTJVgZ78ocve2y6sJyglGSRarwLP16qwvXMWq-zN1q2xHxnQbFVs9rvYwI-_Qn3eYvmDv5sM4HQN2tZlHS7b_3M-AR6npWg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1865217881</pqid></control><display><type>article</type><title>More on Treatment Outcomes in Multidrug-Resistant Tuberculosis</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>New England Journal of Medicine</source><creator>Salfinger, Max ; Somoskovi, Akos ; Diacon, Andreas H ; Van Baelen, Ben ; Theeuwes, Myriam ; Brust, James C.M ; Shah, N. Sarita ; Gandhi, Neel R ; Lange, Christoph ; Günther, Gunar ; van Leth, Frank</creator><creatorcontrib>Salfinger, Max ; Somoskovi, Akos ; Diacon, Andreas H ; Van Baelen, Ben ; Theeuwes, Myriam ; Brust, James C.M ; Shah, N. Sarita ; Gandhi, Neel R ; Lange, Christoph ; Günther, Gunar ; van Leth, Frank ; TBNET</creatorcontrib><description>To the Editor:
Zignol et al. (Sept. 15 issue)
1
suggest that within 10 years, molecular technologies will replace conventional phenotypic testing in surveys of drug resistance and surveillance of tuberculosis. To avoid the overestimation of drug resistance, wider implementation of testing for minimal inhibitory concentration (MIC) must occur first, for four main reasons. First, most commercial molecular assays do not provide information on the type of mutation. Second, different mutation types may be associated with different phenotypic MICs and different clinically relevant levels of resistance, which may lead to unnecessary discontinuation of a drug or incorrectly identifying a patient as . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMc1613123</identifier><identifier>PMID: 28029919</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Antitubercular Agents - therapeutic use ; Drug resistance ; Humans ; Minimum inhibitory concentration ; Multidrug resistance ; Mutation ; Mycobacterium tuberculosis ; Retrospective Studies ; Treatment Outcome ; Tuberculosis ; Tuberculosis, Multidrug-Resistant - drug therapy</subject><ispartof>The New England journal of medicine, 2016-12, Vol.375 (26), p.2609-2611</ispartof><rights>Copyright © 2016 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4703-14a1b67fd0b2f8ba8ea12302baa1c7ef4d893823f7bfee6247bf7b3115d391083</citedby><cites>FETCH-LOGICAL-c4703-14a1b67fd0b2f8ba8ea12302baa1c7ef4d893823f7bfee6247bf7b3115d391083</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMc1613123$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMc1613123$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,776,780,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28029919$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Salfinger, Max</creatorcontrib><creatorcontrib>Somoskovi, Akos</creatorcontrib><creatorcontrib>Diacon, Andreas H</creatorcontrib><creatorcontrib>Van Baelen, Ben</creatorcontrib><creatorcontrib>Theeuwes, Myriam</creatorcontrib><creatorcontrib>Brust, James C.M</creatorcontrib><creatorcontrib>Shah, N. Sarita</creatorcontrib><creatorcontrib>Gandhi, Neel R</creatorcontrib><creatorcontrib>Lange, Christoph</creatorcontrib><creatorcontrib>Günther, Gunar</creatorcontrib><creatorcontrib>van Leth, Frank</creatorcontrib><creatorcontrib>TBNET</creatorcontrib><title>More on Treatment Outcomes in Multidrug-Resistant Tuberculosis</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>To the Editor:
Zignol et al. (Sept. 15 issue)
1
suggest that within 10 years, molecular technologies will replace conventional phenotypic testing in surveys of drug resistance and surveillance of tuberculosis. To avoid the overestimation of drug resistance, wider implementation of testing for minimal inhibitory concentration (MIC) must occur first, for four main reasons. First, most commercial molecular assays do not provide information on the type of mutation. Second, different mutation types may be associated with different phenotypic MICs and different clinically relevant levels of resistance, which may lead to unnecessary discontinuation of a drug or incorrectly identifying a patient as . . .</description><subject>Antitubercular Agents - therapeutic use</subject><subject>Drug resistance</subject><subject>Humans</subject><subject>Minimum inhibitory concentration</subject><subject>Multidrug resistance</subject><subject>Mutation</subject><subject>Mycobacterium tuberculosis</subject><subject>Retrospective Studies</subject><subject>Treatment Outcome</subject><subject>Tuberculosis</subject><subject>Tuberculosis, Multidrug-Resistant - drug therapy</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqN0UtLxDAUBeAgio6jO9dS0IULq7l5Nd0IMowvHAdkXJe0vZUOfWjSLPz3ZhgVEReTzYXk4xDuIeQI6AVQqS6fpg-zAhRwYHyLjEByHgtB1TYZUcp0LJKU75F955Y0HBDpLtljmrI0hXRErma9xajvooVFM7TYDdHcD0XfoovqLpr5ZqhL61_jZ3S1G0x4X_gcbeGbPlwckJ3KNA4Pv-aYvNxMF5O7-HF-ez-5fowLkVAegzCQq6Qqac4qnRuNJvyWstwYKBKsRKlTrhmvkrxCVEyEmeQcQJY8Bar5mJytc99s_-7RDVlbuwKbxnTYe5eBlgKoUlxsSqXclEoZlrsZFTJVgZ78ocve2y6sJyglGSRarwLP16qwvXMWq-zN1q2xHxnQbFVs9rvYwI-_Qn3eYvmDv5sM4HQN2tZlHS7b_3M-AR6npWg</recordid><startdate>20161229</startdate><enddate>20161229</enddate><creator>Salfinger, Max</creator><creator>Somoskovi, Akos</creator><creator>Diacon, Andreas H</creator><creator>Van Baelen, Ben</creator><creator>Theeuwes, Myriam</creator><creator>Brust, James C.M</creator><creator>Shah, N. Sarita</creator><creator>Gandhi, Neel R</creator><creator>Lange, Christoph</creator><creator>Günther, Gunar</creator><creator>van Leth, Frank</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20161229</creationdate><title>More on Treatment Outcomes in Multidrug-Resistant Tuberculosis</title><author>Salfinger, Max ; Somoskovi, Akos ; Diacon, Andreas H ; Van Baelen, Ben ; Theeuwes, Myriam ; Brust, James C.M ; Shah, N. Sarita ; Gandhi, Neel R ; Lange, Christoph ; Günther, Gunar ; van Leth, Frank</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4703-14a1b67fd0b2f8ba8ea12302baa1c7ef4d893823f7bfee6247bf7b3115d391083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Antitubercular Agents - therapeutic use</topic><topic>Drug resistance</topic><topic>Humans</topic><topic>Minimum inhibitory concentration</topic><topic>Multidrug resistance</topic><topic>Mutation</topic><topic>Mycobacterium tuberculosis</topic><topic>Retrospective Studies</topic><topic>Treatment Outcome</topic><topic>Tuberculosis</topic><topic>Tuberculosis, Multidrug-Resistant - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Salfinger, Max</creatorcontrib><creatorcontrib>Somoskovi, Akos</creatorcontrib><creatorcontrib>Diacon, Andreas H</creatorcontrib><creatorcontrib>Van Baelen, Ben</creatorcontrib><creatorcontrib>Theeuwes, Myriam</creatorcontrib><creatorcontrib>Brust, James C.M</creatorcontrib><creatorcontrib>Shah, N. Sarita</creatorcontrib><creatorcontrib>Gandhi, Neel R</creatorcontrib><creatorcontrib>Lange, Christoph</creatorcontrib><creatorcontrib>Günther, Gunar</creatorcontrib><creatorcontrib>van Leth, Frank</creatorcontrib><creatorcontrib>TBNET</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Salfinger, Max</au><au>Somoskovi, Akos</au><au>Diacon, Andreas H</au><au>Van Baelen, Ben</au><au>Theeuwes, Myriam</au><au>Brust, James C.M</au><au>Shah, N. Sarita</au><au>Gandhi, Neel R</au><au>Lange, Christoph</au><au>Günther, Gunar</au><au>van Leth, Frank</au><aucorp>TBNET</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>More on Treatment Outcomes in Multidrug-Resistant Tuberculosis</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2016-12-29</date><risdate>2016</risdate><volume>375</volume><issue>26</issue><spage>2609</spage><epage>2611</epage><pages>2609-2611</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>To the Editor:
Zignol et al. (Sept. 15 issue)
1
suggest that within 10 years, molecular technologies will replace conventional phenotypic testing in surveys of drug resistance and surveillance of tuberculosis. To avoid the overestimation of drug resistance, wider implementation of testing for minimal inhibitory concentration (MIC) must occur first, for four main reasons. First, most commercial molecular assays do not provide information on the type of mutation. Second, different mutation types may be associated with different phenotypic MICs and different clinically relevant levels of resistance, which may lead to unnecessary discontinuation of a drug or incorrectly identifying a patient as . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>28029919</pmid><doi>10.1056/NEJMc1613123</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2016-12, Vol.375 (26), p.2609-2611 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1854106634 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; New England Journal of Medicine |
| subjects | Antitubercular Agents - therapeutic use Drug resistance Humans Minimum inhibitory concentration Multidrug resistance Mutation Mycobacterium tuberculosis Retrospective Studies Treatment Outcome Tuberculosis Tuberculosis, Multidrug-Resistant - drug therapy |
| title | More on Treatment Outcomes in Multidrug-Resistant Tuberculosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T04%3A35%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=More%20on%20Treatment%20Outcomes%20in%20Multidrug-Resistant%20Tuberculosis&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Salfinger,%20Max&rft.aucorp=TBNET&rft.date=2016-12-29&rft.volume=375&rft.issue=26&rft.spage=2609&rft.epage=2611&rft.pages=2609-2611&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMc1613123&rft_dat=%3Cproquest_cross%3E1854106634%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1865217881&rft_id=info:pmid/28029919&rfr_iscdi=true |